The 2026 Shanghai (Qingpu) Biopharma Development Forum was held in Qingpu District on April 15, bringing together experts, leading biopharma executives and top investment institutions to discuss cutting-edge trends and pathways for innovation and collaboration.

Under the theme "New Pharmaceutical Landscape, New Growth Drivers for China," the forum was co-hosted by Shanghai State-owned Capital Investment Guidance Fund, Qingpu Investment HoldingsGroup andLoyal ValleyCapital.

The forum featured keynote speeches and roundtable dialogues, with more than 40 leading companies from specialized sectors participating. Discussions covered the growth of innovative biopharma companies, overseas expansion of technology-platform biotech firms, and investment opportunities in capital markets. Topics spanned the entire industry chain, including innovative drugs, cell and gene therapies, high-end medical devices, industrial translation and cross-border collaboration.

During the forum, Qingpu District delivered a special presentation on its biopharma industrial environment. Leveraging city-district joint funds, industrial park infrastructure and clinical resource advantages, Qingpu will continue to build an innovation-driven R&D ecosystem, expand clinical application scenarios and improve industry-finance linkage mechanisms. The district aims to attract more high-quality enterprises, advanced projects and innovative talent, accelerating the formation of a biopharma industrial cluster with regional influence.